Spironolactone vs Vaniqa (Eflornithine): Which Is Better for PCOS Hair Growth, and Can You Switch?

What Is Spironolactone, and How Does It Treat PCOS Hair Growth?

Spironolactone reduces androgen-driven hair growth by blocking androgen receptors and lowering ovarian testosterone production. In PCOS, excess androgens stimulate the pilosebaceous unit, producing thicker, darker terminal hairs in androgen-sensitive areas: the chin, upper lip, jaw, chest, and lower abdomen. Spironolactone interrupts that signal at the receptor level rather than at the hair follicle itself.

How Spironolactone Reduces Androgens

Originally developed as a mineralocorticoid receptor antagonist for hypertension and heart failure, spironolactone also acts as a competitive antagonist at the androgen receptor. At doses used for hirsutism (typically 75-200 mg/day), it reduces the binding of testosterone and dihydrotestosterone (DHT) to follicular receptors. At higher doses it may also reduce adrenal androgen synthesis, which matters in PCOS where adrenal androgen excess is present in roughly 20-30% of affected women.

Evidence in PCOS

The 2015 Cochrane review of anti-androgens for hyperandrogenism and hirsutism in PCOS examined 35 randomized controlled trials and found that spironolactone produced a statistically significant reduction in Ferriman-Gallwey hirsutism scores compared to placebo. The review noted meaningful reductions at doses of 100 mg/day and above, with the effect increasing incrementally at 200 mg/day. Spironolactone performed comparably to finasteride and flutamide on hirsutism scores, and outperformed metformin in direct comparisons for hair-growth endpoints.

What Spironolactone Does Not Do

Spironolactone does not remove hair that already exists. It slows new terminal hair growth over 3-6 months, so existing hairs must still be removed by shaving, threading, waxing, or laser. Women sometimes abandon treatment early because they expect visible results before the 3-month mark. That expectation mismatch is one of the most common clinical reasons providers add Vaniqa as a bridge during the waiting period.

What Is Vaniqa (Eflornithine 13.9%), and How Does It Work?

Vaniqa is a prescription topical cream containing eflornithine hydrochloride at 13.9%. It works by irreversibly inhibiting ornithine decarboxylase (ODC), an enzyme in the hair follicle that is required for cell proliferation in the hair matrix. By blocking ODC, eflornithine slows the rate at which hairs grow back after removal. It does not destroy follicles and does not affect androgen levels.

The Key Clinical Trial

The key RCT supporting FDA approval was a 24-week, multicenter, double-blind, vehicle-controlled trial in 594 women with unwanted facial hair. Participants applied eflornithine 13.9% or vehicle twice daily after their usual hair removal method. At week 24, 58% of eflornithine-treated women showed improvement on the Global Improvement Score compared with 34% in the vehicle group (P < 0.001). Hair regrowth slowed measurably by week 8. Hair returned to baseline within 8 weeks of stopping treatment, confirming the effect is suppressive, not curative.

What Vaniqa Does Not Do

Vaniqa does not treat the androgen excess driving PCOS. It does not lower testosterone, improve insulin sensitivity, restore cycle regularity, or protect against the long-term metabolic complications of PCOS. It acts only at the follicle surface. Women with PCOS using Vaniqa alone will see slower facial hair regrowth but will still have the underlying hormonal condition progressing without systemic treatment.

Spironolactone vs Vaniqa: A Direct Comparison

No published head-to-head randomized trial has compared spironolactone directly to eflornithine 13.9% in women with PCOS as of early 2025. The comparison below synthesizes the available evidence from separate trial programs.

Mechanism and Target

| Feature | Spironolactone | Vaniqa (Eflornithine 13.9%) | |---|---|---| | Route | Oral | Topical (face only) | | Mechanism | Androgen receptor blockade | ODC enzyme inhibition | | Treats PCOS root cause | Partially (androgen excess) | No | | Body site coverage | Systemic: face, chin, chest, abdomen | Face only (approved label) | | Onset of hair effect | 3-6 months | 4-8 weeks for slowed regrowth | | Effect persists off drug | Gradual return over weeks to months | Returns within 8 weeks | | Prescription required | Yes | Yes | | Average monthly cost (US, uninsured) | $15-40 generic | $80-150+ brand |

Side Effects by Drug

Spironolactone's most common side effects in women include menstrual irregularities in up to 22% of users, breast tenderness, increased urinary frequency, and dose-dependent dizziness from its diuretic effect. Hyperkalemia is a real risk at higher doses; baseline potassium and renal function checks are standard before initiating treatment, particularly if you also take NSAIDs, ACE inhibitors, or potassium-containing supplements.

Vaniqa's side effects are largely local: stinging, burning, rash, and acneiform eruptions at the application site occur in roughly 3-8% of users in trial data. These are rarely severe enough to discontinue treatment. There are no systemic potassium or blood pressure concerns because percutaneous absorption is minimal.

Who Responds Better to Which Drug

The following clinical framework is used internally at WomanRx to guide initial drug selection and switching decisions. No single published guideline maps these criteria in this combined format.

Consider spironolactone first if you:

• Have confirmed or suspected PCOS with elevated free testosterone or DHEA-S
• Also have hormonal acne, seborrhea, or androgenic alopecia (female pattern hair loss)
• Have blood pressure on the higher end of normal or hypertension
• Want systemic treatment for hirsutism in multiple body regions (not just face)
• Are not currently trying to conceive and are using reliable contraception

Consider Vaniqa first (or in addition to spironolactone) if you:

• Cannot tolerate or have contraindications to systemic anti-androgens
• Are waiting for spironolactone's effects to start (weeks 0 to 12)
• Have facial hair as your only target and prefer a topical-only approach
• Are in the perimenopause window and have normal or low-normal androgens
• Are post-menopause and have mild facial vellus-to-terminal conversion without significant androgen excess

Across Life Stages: Which Drug Fits Where?

Hirsutism and facial hair change across the female lifespan. The right treatment at 22 may not be the right treatment at 44.

Reproductive Years (Ages 18-40) and PCOS

In women of reproductive age with PCOS, spironolactone is the most commonly prescribed systemic option in the United States for hirsutism when oral contraceptives alone are insufficient. The Endocrine Society's 2018 PCOS guideline recommends hormonal contraceptives as first-line and anti-androgens such as spironolactone as second-line. At this life stage, the teratogenic risk of spironolactone makes combined oral contraceptive cover non-negotiable (see Pregnancy section below).

Vaniqa can be used alongside an OCP plus spironolactone in this age group. Combination with laser hair removal is particularly practical: laser requires 4-6 sessions spaced 6-8 weeks apart to achieve meaningful reduction, and Vaniqa can reduce visible regrowth between sessions.

Trying to Conceive

Spironolactone must be stopped at least one full menstrual cycle before any pregnancy attempt. Most clinicians recommend stopping 1-3 months before trying to conceive to allow the anti-androgenic effect to clear and to confirm cycle normalization. Vaniqa is not recommended in pregnancy (see below), so women actively trying to conceive should transition to mechanical removal only.

Perimenopause (Ages 40-55, Irregular Cycles)

Androgen excess in perimenopause is more nuanced. Estrogen falls faster than testosterone in early perimenopause, which can paradoxically worsen androgenic symptoms including facial hair and scalp hair thinning in women who never had PCOS. In women with pre-existing PCOS entering perimenopause, symptoms may temporarily worsen before improving after menopause.

Spironolactone at lower doses (25-75 mg) remains an option in perimenopausal women if contraception is maintained while any possibility of ovulation persists. Vaniqa becomes more appealing at this stage because many perimenopausal women have mild-to-moderate androgen excess that does not justify systemic anti-androgen therapy but produces cosmetically distressing facial hair.

Post-Menopause

After confirmed menopause (12 consecutive months without a period), androgen levels fall further as ovarian androgen production declines. Facial vellus-to-terminal conversion driven by the new estrogen-to-androgen ratio can persist. Spironolactone is sometimes continued or initiated post-menopause for hirsutism or female pattern hair loss, without any contraception requirement. Vaniqa is a reasonable monotherapy at this stage for women who prefer to avoid systemic medication.

Pregnancy, Lactation, and Contraception: What Every Woman Needs to Know

This section is mandatory reading if you are using either drug and have any possibility of pregnancy.

Spironolactone in Pregnancy

Spironolactone is classified as pregnancy category C/D depending on trimester under the old FDA system, and is associated with anti-androgenic feminization of male fetuses in animal studies. Human data are limited, but the mechanism of action (androgen receptor blockade) creates a biologically plausible risk of genital ambiguity in a male fetus during organogenesis. This risk alone is sufficient reason for the drug to carry a strong contraindication in pregnancy.

You must use reliable contraception while taking spironolactone. Most providers co-prescribe a combined oral contraceptive, which also independently reduces androgen levels, making the combination more effective for PCOS hirsutism and acne than either drug alone. If you rely on progestin-only methods or copper IUD without estrogen, discuss the plan explicitly with your prescriber because cycle irregularity from spironolactone can make natural-cycle-based contraceptive monitoring unreliable.

If you become pregnant while taking spironolactone, stop the drug immediately and contact your obstetric provider. The absolute risk from brief first-trimester exposure in humans is not well quantified, but animal data are concerning enough that no unnecessary exposure should continue.

Eflornithine (Vaniqa) in Pregnancy and Lactation

Eflornithine is FDA pregnancy category C. Animal reproductive studies showed adverse effects at high systemic doses. Human data from topical use are extremely limited because the drug was excluded from pregnancy trials. Percutaneous absorption of the 13.9% cream is low (about 0.6% of the applied dose reaches systemic circulation), but the absence of safety data means most clinicians advise against use during pregnancy or active breastfeeding.

Lactation transfer of topically applied eflornithine has not been studied. Given unknown transfer and the availability of mechanical hair removal alternatives, Vaniqa should be paused during breastfeeding unless a clinician explicitly determines the benefit outweighs the uncertainty.

Practical Contraception Checklist for Women on Spironolactone

• Confirm a reliable contraceptive method before starting spironolactone.
• A combined oral contraceptive containing 30-35 mcg ethinyl estradiol plus a progestin with low androgenic activity (such as norgestimate or drospirenone) adds independent anti-androgenic and cycle-regulating benefits.
• Drospirenone-containing pills (e.g., Yasmin, Yaz) have their own mild anti-androgenic and aldosterone-blocking properties; combined with spironolactone, potassium monitoring is particularly important.
• Document your current method, last menstrual period, and any symptoms of pregnancy at every follow-up appointment.

Switching Between Spironolactone and Vaniqa

Switching is common and is usually driven by one of four clinical situations: pregnancy planning, inadequate response, side effect intolerance, or the desire to add a topical drug during the systemic drug's slow onset window.

Situation 1: Switching From Spironolactone to Vaniqa Because You Are Trying to Conceive

Stop spironolactone at least one full menstrual cycle (ideally two to three cycles) before attempting conception. During that washout window, mechanical removal is the only safe option. Do not start Vaniqa as a bridge if conception is the immediate goal, because Vaniqa is not recommended in pregnancy.

Situation 2: Adding Vaniqa While Waiting for Spironolactone to Work

This is probably the most clinically rational combination. Spironolactone requires a minimum of three months and often six months before patients notice slower, finer regrowth. Vaniqa begins slowing hair regrowth at 4-8 weeks. Starting both simultaneously gives a woman cosmetic improvement on the shorter timeline while spironolactone builds its hormonal effect. Once spironolactone is working well (typically at the 6-month mark), Vaniqa can be continued or tapered off based on patient preference.

Situation 3: Switching From Spironolactone to Vaniqa Due to Side Effects

Menstrual irregularity is the most common reason women stop spironolactone: up to 22% of users report cycle disturbance. If lowering the dose or adjusting the accompanying OCP does not resolve menstrual irregularity, transitioning to Vaniqa monotherapy is a reasonable step, with the understanding that the underlying PCOS androgen excess will no longer be systemically addressed. A frank conversation about long-term PCOS metabolic management (insulin resistance, cycle regulation, cardiovascular risk) is warranted at that transition point.

Situation 4: Adding Spironolactone to Vaniqa When Topical Treatment Alone Is Insufficient

Women who started with Vaniqa and find their facial hair is progressing despite consistent twice-daily use may have significant underlying androgen excess that warrants systemic treatment. A free testosterone, DHEA-S, and SHBG panel can clarify whether the driver is androgenic. If lab results confirm hyperandrogenism, spironolactone (or in some regions, flutamide or cyproterone acetate) is the logical addition.

Female-Specific Conditions This Comparison Touches

Both drugs intersect with several conditions common in women beyond PCOS alone.

Idiopathic Hirsutism

Approximately 5-15% of women with hirsutism have normal androgen levels and regular cycles. In idiopathic hirsutism, the hair follicle appears more sensitive to normal circulating androgens. Spironolactone remains effective because it blocks the androgen receptor regardless of whether circulating levels are elevated. Vaniqa is equally effective regardless of androgen status, making it a particularly good fit here.

Female Pattern Hair Loss (Androgenic Alopecia)

Spironolactone at 100-200 mg/day is used off-label for female pattern hair loss, where DHT-driven follicular miniaturization on the scalp is the mechanism. The Ferriman-Gallwey score measures hirsutism on the body, not scalp loss, but the same anti-androgenic mechanism that reduces facial terminal hairs may slow scalp miniaturization. Vaniqa has no evidence base for scalp use and is not an option for this indication.

Hormonal Acne

Spironolactone's anti-androgenic action also reduces sebum production, making it highly useful when a PCOS patient has both facial hair and moderate-to-severe comedonal or inflammatory acne. Vaniqa has no mechanism of action on sebaceous glands and does not treat acne.

Postpartum Rebound Hirsutism

Some women notice increased facial terminal hair in the months after delivery, related to the postpartum drop in estrogen and the relative (though temporary) androgenic dominance. This is generally self-limiting, but postpartum women who are breastfeeding cannot use spironolactone (transfer to breast milk is poorly characterized, and its potassium-sparing and anti-androgenic properties make use during lactation inadvisable). Vaniqa is similarly not recommended while breastfeeding. Mechanical removal remains the default option in the postpartum and breastfeeding window.

Evidence Gap: What We Do Not Know Yet

Women have been underrepresented in pharmacological trials. Several honest gaps are worth naming.

First, there is no published head-to-head randomized controlled trial comparing spironolactone to eflornithine 13.9% in women with PCOS. All comparative claims are inferences from separate trial programs with different populations, primary outcomes, and follow-up durations.

Second, the 2015 Cochrane review found that most hirsutism trials used subjective Ferriman-Gallwey scoring rather than objective hair growth measures such as digital photography or phototrichogram analysis. This limits precision in cross-drug comparisons.

Third, long-term safety data for spironolactone at doses above 100 mg/day in premenopausal women over periods exceeding two years are sparse. Most trial follow-up periods are 6-12 months.

Fourth, the eflornithine trial that underpins FDA approval enrolled 594 women but was not enriched for PCOS, so the response rate in women with confirmed PCOS and elevated androgens vs. Women with idiopathic hirsutism is not broken out in published data.

Who This Is Right For (and Who Should Think Twice)

Spironolactone Is a Strong Fit If

• You have PCOS confirmed by Rotterdam criteria or clinical hyperandrogenism
• You want to treat hirsutism AND hormonal acne AND possible androgenic hair thinning with one systemic drug
• You are using reliable hormonal contraception and not planning pregnancy in the next 6 months
• Your blood pressure runs normal or elevated (the diuretic effect is a benefit, not a concern)
• Potassium is normal and renal function is adequate

Spironolactone Warrants Caution or Is Not Right If

• You are pregnant, trying to conceive, or cannot use reliable contraception
• You have renal impairment or baseline hyperkalemia
• You are also taking ACE inhibitors, ARBs, or potassium-sparing diuretics (additive hyperkalemia risk)
• You have a history of significant menstrual irregularity that worsens with the drug and cannot be managed with combined OCP

Vaniqa Is a Strong Fit If

• Facial hair is the only concern and you prefer to avoid systemic treatment
• You want faster cosmetic improvement while systemic therapy starts to work
• You are in perimenopause or post-menopause with mild facial vellus-to-terminal conversion and low or normal androgens
• You are undergoing laser hair removal and want to slow regrowth between sessions
• You have contraindications to systemic anti-androgens

Vaniqa Is Not the Right Choice If

• You expect it to address PCOS, acne, or body-site hirsutism beyond the face
• You are pregnant or breastfeeding
• You have active skin breakdown or dermatitis in the application area
• Cost is a primary barrier and your insurer does not cover the brand product